Navigation Links
Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
Date:7/15/2008

Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard

Treatment, According to a New Report from Decision Resources

WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's long-term efficacy in preventing recurrence of depressive mood episodes in patients who suffer from major depressive disorder, is the attribute that most influences psychiatrists' prescribing decisions in the treatment of this disorder. Clinical data and expert opinion show that current and emerging therapies will continue to struggle for patient share through subtle differences in efficacy, tolerability and delivery.

The new report entitled Major Depressive Disorder: Long-Term Efficacy Would Differentiate a New Drug in the Crowded Antidepressant Market finds that if an agent preventing recurrence of depressive mood episodes superior to that of sales-leading Wyeth's Effexor XR were to be launched, it would earn a 25 percent patient share, according to surveyed psychiatrists. The report also finds that although Effexor XR is the sales leader in the major depressive disorder drug market, the current and future Decision Resources proprietary clinical gold standard treatment for the indication is escitalopram (Lundbeck's Cipralex/Seroplex; Forest's Lexapro).

Although escitalopram's efficacy is not the highest in our study, the drug outscored any other current therapy in the area of safety. Experts we interviewed explain that because the drug is an active metabolite, lower doses can be used, an advantage that results in safety benefits.

"Based on available data and expert opinion, we do not expect any therapy under development to displace escitalopram as the clinical gold standard for major depressive disorder," said Carlos Dedesma, Ph.D., analyst at Decision Resources. "Although some therapies in development hold promise, most of them earned inferior scores in efficacy, safety and tolerability, and/or delivery features when compared with escitalopram."

About the Report

Major Depressive Disorder: Long-Term Efficacy Would Differentiate a New Drug in the Crowded Antidepressant Market is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
2. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
3. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
4. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
5. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
10. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
11. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... focused on delivering scientific and medical breakthroughs using ... and Chief Executive Officer Keith Murphy ... December 14, 2016 at 1:00 p.m. Eastern Time ... yet familiar with the Company, an informational video ...
(Date:12/7/2016)... NEW YORK , December 7, 2016 ... by Persistence Market Research titled , Global Market Study on ... Market Through 2024 , the global multiplex detection immunoassay ... the forecast period 2016-2024. ... , , ...
(Date:12/6/2016)... 6, 2016  Licenders is bringing their 100% all-natural lice removal ... Park Slope at 203 13 th Street was specifically chosen ... clientele. "Our goal is to ease parents, stress and ... to get children right back to class without skipping a beat. ... and safe for the whole family," Licenders President Adie Horowitz ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine ... services to families and business owners in the greater Dallas metropolitan area, is ... Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals in ...
(Date:12/7/2016)... Peoria, IL (PRWEB) , ... December 07, 2016 , ... ... holiday season. Many children are not fortunate enough to receive bountiful gifts wrapped ... that unwrapping presents can bring to the children of the world. , In exchange ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... The study was published in the prestigious Journal of Veterinary Science & Medical ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... announce that its fully redesigned website, which launched October 17, 2016, features comprehensive ... responsive design and easy-to-navigate layout. Visitors and patients can discover the latest clinical ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Delete® - Tattoo ... Time For The Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® ... is providing the Phoenix Valley with Delightful Deals on Botox® and Juvederm® ...
Breaking Medicine News(10 mins):